Poolbeg Pharma has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza.
Key highlights:
- The trial will assess the efficacy of POLB 001 in dampening the robust immune response to LPS which acts as a surrogate for the hyperinflammatory response associated with severe influenza and other diseases.
- Initial results expected in Q4 2022 at which point the company intends to rapidly monetise by out-licensing / partnering with pharma and biotech companies for further development of POLB 001.
- Trial success could also pave the way for potential applications beyond severe influenza.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
